| Dr Michael Richard Banyas, MD | |
|
3260 Hospital Dr, Juneau, AK 99801-7808 | |
| (206) 855-9263 | |
| Not Available |
| Full Name | Dr Michael Richard Banyas |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 35 Years |
| Location | 3260 Hospital Dr, Juneau, Alaska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609848787 | NPI | - | NPPES |
| MD3312 | Medicaid | AK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MD3312 (Alaska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Washington Medical Ctr | Seattle, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Association Of University Physicians | 0446162697 | 3009 |
News Archive
Akorn, Inc. a specialty pharmaceutical company, today reported financial results for the third quarter ended September 30, 2009.
Next Generation Sequencing (NGS) technology offers an incredible opportunity for the rapid and relatively low-cost characterization of individual genomes, giving us a chance to make a substantial leap ahead in the molecular dissection of all mitochondrial disorders in humans.
Researchers at the University of California, San Francisco, National Jewish Health and Centro de Neumología Pediátrica in Puerto Rico have been awarded nearly $10 million as part of a 5-year grant from the U.S. National Heart Lung and Blood Institute, part of the National Institutes of Health, to address the root causes of asthma by studying 4,000 children in Puerto Rico, where asthma prevalence and deaths are among the highest in the world.
Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced today that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for nonpegylated liposomal doxorubicin (Myocet(TM)) for first-line therapy of HER2 positive metastatic breast cancer.
› Verified 7 days ago
| Entity Name | The Association Of University Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023041159 PECOS PAC ID: 0446162697 Enrollment ID: O20031105000244 |
News Archive
Akorn, Inc. a specialty pharmaceutical company, today reported financial results for the third quarter ended September 30, 2009.
Next Generation Sequencing (NGS) technology offers an incredible opportunity for the rapid and relatively low-cost characterization of individual genomes, giving us a chance to make a substantial leap ahead in the molecular dissection of all mitochondrial disorders in humans.
Researchers at the University of California, San Francisco, National Jewish Health and Centro de Neumología Pediátrica in Puerto Rico have been awarded nearly $10 million as part of a 5-year grant from the U.S. National Heart Lung and Blood Institute, part of the National Institutes of Health, to address the root causes of asthma by studying 4,000 children in Puerto Rico, where asthma prevalence and deaths are among the highest in the world.
Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced today that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for nonpegylated liposomal doxorubicin (Myocet(TM)) for first-line therapy of HER2 positive metastatic breast cancer.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Richard Banyas, MD 10850 Ne Boulder Pl, Bainbridge Island, WA 98110-3123 Ph: (206) 855-9263 | Dr Michael Richard Banyas, MD 3260 Hospital Dr, Juneau, AK 99801-7808 Ph: (206) 855-9263 |
News Archive
Akorn, Inc. a specialty pharmaceutical company, today reported financial results for the third quarter ended September 30, 2009.
Next Generation Sequencing (NGS) technology offers an incredible opportunity for the rapid and relatively low-cost characterization of individual genomes, giving us a chance to make a substantial leap ahead in the molecular dissection of all mitochondrial disorders in humans.
Researchers at the University of California, San Francisco, National Jewish Health and Centro de Neumología Pediátrica in Puerto Rico have been awarded nearly $10 million as part of a 5-year grant from the U.S. National Heart Lung and Blood Institute, part of the National Institutes of Health, to address the root causes of asthma by studying 4,000 children in Puerto Rico, where asthma prevalence and deaths are among the highest in the world.
Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced today that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for nonpegylated liposomal doxorubicin (Myocet(TM)) for first-line therapy of HER2 positive metastatic breast cancer.
› Verified 7 days ago
Dr. Steven Tudor Parker, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 3260 Hospital Dr, Juneau, AK 99801 Phone: 907-586-2611 | |
Dr. John Thomas Connolly Jr., MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 3260 Hospital Dr, Juneau, AK 99801 Phone: 907-796-8433 | |
Paul M. Skan, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 3260 Hospital Dr, Juneau, AK 99801 Phone: 907-586-2611 | |
Dr. Thomas Chang, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3260 Hospital Dr, Juneau, AK 99801 Phone: 907-796-8925 | |
William S Wood, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 3260 Hospital Dr, Juneau, AK 99801 Phone: 907-586-2611 | |
Dr. Victoria L Sanjuan, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3260 Hospital Dr, Juneau, AK 99801 Phone: 907-796-8900 |